PRF Technologies Ltd. (PRFX)
NasdaqCM: PRFX
· Цена в реальном времени · USD
1.03
-0.17 (-14.17%)
На закрытии: Aug 14, 2026, 3:59 PM
1.01
-1.94%
Постмаркет: 7:55 PM
Описание компании
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
PRF Technologies Ltd.
| Страна | Israel |
| Дата IPO | 1 сент. 2020 г. |
| Отрасль | Drug Manufacturers - Specialty & Generic |
| Сектор | Healthcare |
| Сотрудники | 6 |
| CEO | Mr. Efraim Cohen-Arazi |
Контакты
Адрес: 65 Yigal Alon St. Tel Aviv-Yafo, Israel | |
| Сайт | https://www.painreform.com |
Данные по акции
| Тикер | PRFX |
| Биржа | NasdaqCM |
| Финансовый год | Jan '25 - Dec '25 |
| Валюта отчётности | USD |
| Код CIK | 0001801834 |
| Номер CUSIP | n/a |
| Номер ISIN | n/a |
| Employer ID | n/a |
| Код SIC | n/a |
Ключевые руководители
| Имя | Должность |
|---|---|
| Dr. Ehud Geller Ph.D. | Executive Chairman |
| Mr. Eyal Broder | Chief Financial Officer |
| Dr. Sigal Aviel eMBA, Ph.D. | Chief Operating Officer |
| Mr. Efraim Cohen-Arazi | Interim CEO & Director |
| Ms. Rita Keynan M.Sc. | Vice President of Pharmaceutical Operations |